Jaguar Health, Inc. 8-K/A

What Happened Jaguar Health, Inc. (JAGX) announced on June 22, 2026 that its Board of Directors has initiated a process to explore and review a range of strategic alternatives aimed at maximizing shareholder value. The company filed Amendment No. 1 to its Form 8‑K to replace the previously attached press release with a corrected version; the original exhibit had an incorrect headline. The corrected headline reads: “Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program.” No other changes were made to the original 8‑K.

Key Details

• Press release and Form 8‑K/A filed June 22, 2026 (Amendment No. 1) to correct the exhibit headline.
• Board has launched a formal review of “a range of strategic alternatives” focused on maximizing shareholder value.
• Review is explicitly described as aligned with a targeted NDA filing for the company’s rare disease intestinal failure program.
• The filing does not specify which alternatives are being considered, any timeline, or any assurance of a transaction.

Why It Matters This announcement signals the company is actively evaluating options that could change Jaguar Health’s strategic direction or capital structure (for example, partnerships, asset sales, mergers, or other transactions). The tie to a targeted NDA filing highlights that the company’s rare disease program is a central value driver in the review. Retail investors should note there is no guarantee of a deal or outcome, and such processes often lead to increased news flow and share-price volatility as details emerge. Monitor subsequent SEC filings and company press releases for updates and any concrete proposals or timelines.